title: Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.
abstract: Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.
authors.affiliation: Department of Neurology, Johns Hopkins Hospital, David H. Koch Cancer Research Bldg II, 1550 Orleans Street, Room 1M16, Baltimore, MD 21287, USA.
authors.forename: Roy E
authors.initials: RE
authors.lastname: Strowd
authors.forename: Inas A
authors.initials: IA
authors.lastname: Abuali
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Grossman
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: CNS lymphoma; indolent lymphoma; intrathecal rituximab; low-grade lymphoma